Edwards Lifesciences (EW) stock
Last close $103.88 on 2026-11-19 (-1.28%) · Sector: Healthcare
Edwards Lifesciences is a medical device company best known for heart valves, including replacement valves that can be placed without open-heart surgery. It also makes hemodynamic monitoring tools that help doctors track blood flow and heart function in hospitals, and it earns most of its money by selling these products to hospitals and clinics around the world.
Edwards's business is growing steadily, with revenue up 13.6% over the past year and a very strong balance sheet. The shares closed at $103.88, just 3.8% below their 52-week high of $108, and have returned 23.5% over the past year versus 9.7% for the S&P 500. The stock sits well above its 50-day and 200-day averages, which shows recent upward momentum, but it also looks expensive with a P/E of 58.7. Company insiders sold about $10.9 million of stock over the last 90 days and made no purchases.
Key numbers
- Market cap: $60.0B
- Revenue (last 12 months): $6.68B
- Revenue growth: +13.6%
- Gross margin: 78.0%
- Operating margin: 21.6%
- P/E: 58.7
- P/S: 9.0
- Debt to equity: 0.06
- Current ratio: 4.59
Quality score
Overall 44/100 · growth 41 · profitability 46 · financial health 90 · value 0
Performance and risk
1-year return +23.5% vs S&P 500 +9.7% · volatility 25.5% (S&P 500 13.8%) · largest drop -13.2% · beta 0.52
Stock move the day after earnings
- 2026-02-10: +3.0%
- 2026-04-23: +5.6%
- 2026-07-23: -1.4%
- 2026-11-04: +1.5%
Insider trades (12 months)
Bought $0.0M · sold $34.1M
EW stock research · EW options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.